Intepirdine fails to treat Alzheimer ’s disease in Phase 3 trial

Axovant Sciences today announced that the  Phase 3 MINDSET trial of its Alzheimer’s drug intepirdine has failed to bring meaningful improvements in cognition or daily functioning.

Source: Alzheimers Society - September 26, 2017 Category: Geriatrics Source Type: news